Market Overview:
The global progressive relapsing multiple sclerosis treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of progressive relapsing multiple sclerosis, rising awareness about available treatments, and growing investments by key players in research and development. Based on type, the global progressive relapsing multiple sclerosis treatment market is segmented into COG-133, GZ-402668, Inebilizumab, VCE-0032, and others. Based on application, the market is segmented into clinic settings, hospital settings,, and others. Geographically speaking,, North America dominates the global progressive relapsing multiple sclerosis treatment market followed by Europe., Asia Pacific is projected to be fastest growing region over the forecast period owing to increasing prevalence of MS cases in countries such as China and India., Latin America holds a significant share of this market due to rising awareness about available treatments among patients in countries such as Brazil.
Product Definition:
Progressive relapsing multiple sclerosis (PRMS) is a rare form of the disease in which people experience a gradual decline in their physical abilities, followed by occasional relapses that worsen symptoms. There is no known cure for PRMS, but treatment can help manage symptoms and improve quality of life.
COG-133:
COG-133 is a novel, potent, oral small molecule inhibitor of the S1P receptor with high selectivity and affinity. The drug has completed Phase II clinical trial for the treatment of relapsing-remitting multiple sclerosis. It has also completed Phase I clinical trial for treatment-resistant progressive multiple sclerosis (MS).
The primary endpoint in all three trials was safety.
GZ-402668:
GZ-402668 is a drug developed by Novartis AG for the treatment of relapsing multiple sclerosis. It was first approved in 2015 in Europe and has since then gained popularity across the globe. The drug’s mechanism of action remains unknown, although it is believed to be an immunomodulatory molecule as it enhances T cell activity against myelin sheath proteins and reduces inflammation.
Application Insights:
The others segment held the largest share of more than 60.0% in 2017. Others application category includes hospital-based, outpatient and self-management programs. Hospital based treatment is expected to witness a lucrative CAGR during the forecast period owing to increasing number of patients suffering from relapsing remitting MS at a global level coupled with rising awareness about available treatment options at present time.
Clinic based therapies are preferred over hospital-based due to accessibility for follow up appointments and treatments as well as availability of specialists in case any new health complications arise after finishing therapy or if any other unanswered questions remain regarding disease course or diagnosis remains unanswered by current knowledge base among other factors such as insurance coverage etc., which may lead towards adoption of these therapies subsequently resulting in higher growth rate for this segment during the forecast period compared to others segments growth rate globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high disease prevalence, and availability of effective treatment methods are some factors attributing to its largest share. In addition, increasing awareness about multiple sclerosis treatments is also expected to drive the regional market over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to an increase in healthcare expenditure by governments and private organizations as well as rising patient awareness levels regarding available treatment options for relapsing forms of multiple sclerosis. Moreover, growing medical tourism industry due to low cost treatment offered by countries such as India and China is further anticipated boost growth rates in this region during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of progressive relapsing multiple sclerosis (PRMS)
- Growing awareness about PRMS and its treatment options
- Rising demand for better and more effective therapies for PRMS patients
- Availability of novel therapies with better efficacy and safety profiles
- Growing investment in research and development activities for the development of new treatments for PRMS
Scope Of The Report
Report Attributes
Report Details
Report Title
Progressive Relapsing Multiple Sclerosis Treatment Market Research Report
By Type
COG-133, GZ-402668, Inebilizumab, VCE-0032, Others
By Application
Clinic, Hopital, Others
By Companies
Cognosci Inc, Genzyme Corp, MedImmune LLC, VivaCell Biotechnology Espana SL
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Progressive Relapsing Multiple Sclerosis Treatment Market Report Segments:
The global Progressive Relapsing Multiple Sclerosis Treatment market is segmented on the basis of:
Types
COG-133, GZ-402668, Inebilizumab, VCE-0032, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hopital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cognosci Inc
- Genzyme Corp
- MedImmune LLC
- VivaCell Biotechnology Espana SL
Highlights of The Progressive Relapsing Multiple Sclerosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- COG-133
- GZ-402668
- Inebilizumab
- VCE-0032
- Others
- By Application:
- Clinic
- Hopital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Progressive Relapsing Multiple Sclerosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for progressive relapsing multiple sclerosis will vary depending on the individual's specific situation and symptoms. However, some common treatments for progressive relapsing multiple sclerosis include:nnPhysical therapy : Physical therapy may help improve mobility and function in people with progressive relapsing multiple sclerosis.nn: Physical therapy may help improve mobility and function in people with progressive relapsing multiple sclerosis. Medications : Some medications can help reduce inflammation and pain in people with Progressive Relapsing Multiple Sclerosis. These medications can also slow down or stop the progression of the disease.nn: Some medications can help reduce inflammation and pain in people with Progressive Relapsing Multiple Sclerosis. These medications can also slow down or stop the progression of the disease. Surgery : Surgery may be necessary to remove damaged tissue or organs in people with Progressive Relapsing Multiple Sclerosis if other treatments don't work well enough
Some of the major players in the progressive relapsing multiple sclerosis treatment market are Cognosci Inc, Genzyme Corp, MedImmune LLC, VivaCell Biotechnology Espana SL.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Progressive Relapsing Multiple Sclerosis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Progressive Relapsing Multiple Sclerosis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Progressive Relapsing Multiple Sclerosis Treatment Market - Supply Chain
4.5. Global Progressive Relapsing Multiple Sclerosis Treatment Market Forecast
4.5.1. Progressive Relapsing Multiple Sclerosis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Progressive Relapsing Multiple Sclerosis Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Progressive Relapsing Multiple Sclerosis Treatment Market Absolute $ Opportunity
5. Global Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Type
5.3.1. COG-133
5.3.2. GZ-402668
5.3.3. Inebilizumab
5.3.4. VCE-0032
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hopital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Progressive Relapsing Multiple Sclerosis Treatment Demand Share Forecast, 2019-2026
9. North America Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hopital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Type
9.7.1. COG-133
9.7.2. GZ-402668
9.7.3. Inebilizumab
9.7.4. VCE-0032
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Progressive Relapsing Multiple Sclerosis Treatment Demand Share Forecast, 2019-2026
10. Latin America Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hopital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Type
10.7.1. COG-133
10.7.2. GZ-402668
10.7.3. Inebilizumab
10.7.4. VCE-0032
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Progressive Relapsing Multiple Sclerosis Treatment Demand Share Forecast, 2019-2026
11. Europe Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hopital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Progressive Relapsing MultipleSclerosis Treatment Market Size and Volume Forecast by Type
11.7.1. COG-133
11.7.2. GZ-402668
11.7.3. Inebilizumab
11.7.4. VCE-0032
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Progressive Relapsing Multiple Sclerosis Treatment Demand Share, 2019-2026
12. Asia Pacific Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hopital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Type
12.7.1. COG-133
12.7.2. GZ-402668
12.7.3. Inebilizumab
12.7.4. VCE-0032
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Progressive Relapsing Multiple Sclerosis Treatment Demand Share, 2019-2026
13. Middle East & Africa Progressive Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hopital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Progressive Relapsing Multiple Sclerosis Treatment Market Size and Volume Forecast by Type
13.7.1. COG-133
13.7.2. GZ-402668
13.7.3. Inebilizumab
13.7.4. VCE-0032
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Progressive Relapsing Multiple Sclerosis Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Progressive Relapsing Multiple Sclerosis Treatment Market: Market Share Analysis
14.2. Progressive Relapsing Multiple Sclerosis Treatment Distributors and Customers
14.3. Progressive Relapsing Multiple Sclerosis Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Cognosci Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Genzyme Corp
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. MedImmune LLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. VivaCell Biotechnology Espana SL
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
